Corrie P, Terheyden P, ten Tije AJ, et al. A prospective observational safety study of patients (pts) with BRAFV600E-mutated unresectable or metastatic melanoma (MM) treated with vemurafenib (VEM) (Zelboraf Safety Study [ZeSS]): final results. SMR 2017, abstract P17-7.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie